top of page
ProductHomepage_Final.jpg

RoverDx is developing a point-of-care testing device that brings lab based methodology into OB/GYN clinics with results in less then 20 minutes.

RECEIVED 2020

National Institute of Health

RadX grant recipient

NIH_2012_logo_arrow.svg.png
Genophyll_Logo.png

2021 ACQUIRED

Genophyll medical 
laboratory in NJ

nygov-logo.png

AWARDED 2024

New York State Biodefense

Commercialization grant

4c6b1657-214e-439d-bca4-14c07a01ed72_edi

2022 PUBLICATION

RoverDx's nanotechnology

featured in Nature science journal

2022 PUBLICATION

RoverDx's nanotechnology

featured in Nature science journal

WomensHealth1_Final.jpg

RoverDx is passionate about advancing healthcare innovation
for women.  

That's why the first panel we are developing is for women's health. Shortening the time between diagnosis and treatment would improve the well-being of millions of women lives annually.

OUR INITIAL PANEL WILL FOCUS ON THE FOLLOWING CONDITIONS:

Bacterial

Vaginosis

There are 21.2 million cases of bacterial vaginosis reported annually.

1

Vulvovaginal

Candidiasis

An estimated 75% of all women have at least one episode of vulvovaginal candidiasis in their lifetime.

2

Trichomoniasis

70% of patients with trichomoniasis

are asymptomatic.

3

WomensHealth2_Final.jpg

Accurate, easy-to-use,
point-of-care testing  streamlines the treatment process for OB/GYNs. 

Womens’ health is the beginning. RoverDxs Lightspeed technology can be applied to countless conditions, in a broad range of environments —
from nursing homes to field hospitals.
Rover’s team is rolling up their sleeves

bottom of page